Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status
Gail J. Roboz(Cornell University), Hartmut Döhner(University Hospital Ulm), Andre C. Schuh(University of Toronto), Andrew H. Wei(The Royal Melbourne Hospital), C.L. Beach(Université Paris Cité), Daniel L. Menezes(Bristol-Myers Squibb (Germany)), Kimmo Porkka(Helsinki University Hospital), Felicitas Thol(Medizinische Hochschule Hannover), Maria Teresa Voso(University of Rome Tor Vergata), Ignazia La Torre(Hospital Universitari i Politècnic La Fe), Alberto Risueño, Gert J. Ossenkoppele(Dutch Cancer Society), Hervé Dombret(University of London Institute in Paris), Barry Skikne(Boston Children's Hospital), Farhad Ravandi(The University of Texas MD Anderson Cancer Center)
Cited by 63
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k